Second-generation basal insulin analogs achieve similar HbA1c reductions

  • Sullivan SD & al.
  • Diabetes Obes Metab
  • 25 Jun 2018

  • curated by Craig Hicks
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Adults with type 2 diabetes (T2D) who switch from first-generation to second-generation basal insulin analogs achieve similar reductions in HbA1c.

Why this matters

  • This study provides findings that support results from randomized clinical trials and reflect effectiveness in real‐world clinical practice, say researchers.

Study design

  • Researchers studied the electronic medical records of adult patients (n=3184; age ≥18 years) who switched from insulin glargine 100 units/mL (Gla‐100) or insulin detemir (IDet) to insulin glargine 300 units/mL (Gla‐300) or insulin degludec (IDeg).
  • Funding: Sanofi.

Key results

  • Both Gla-300 and IDeg switchers had similar mean decreases in HbA1c and HbA1c goal (
  • No significant differences in hypoglycemia incidence and event rate were found at follow-up for Gla-300 vs IDeg after adjusting for baseline hypoglycemia.

Limitations

  • The treatment effect on hypoglycemia could have been underestimated because self‐monitored blood glucose and continuous blood glucose monitoring data were not available.
  • Follow up was ≤6 months.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit